Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Eli Lilly releases new obesity drug clinical trial data at ObesityWeek
00

Eli Lilly releases new obesity drug clinical trial data at ObesityWeek

Nov 14, 2026

Eli Lilly announced clinical trial results for its obesity treatments for the ObesityWeek 2026 conference. In Phase 3 trials, Lilly's daily pill Foundayo significantly reduced obstructive sleep apnea severity by up to 43.8% and achieved 11% weight loss at 52 weeks, prompting plans for FDA submission by late 2026. Additionally, combination candidate EloraTZP achieved up to 23.3% weight loss in adults with type 2 diabetes, while Zepbound reduced BMI by an average of 21.4% in adolescents.

EloraTZP trial results

  • ▪Eli Lilly's Phase 2 trial results showed that EloraTZP lowered A1C levels by up to an average of 2.9%, with up to 77% of participants achieving normal blood sugar levels
  • ▪Eli Lilly reported at ObesityWeek 2026 that up to 60% of adults taking EloraTZP no longer met the BMI criteria for obesity at 48 weeks
  • ▪Eli Lilly released trial data for the ObesityWeek 2026 medical conference showing that EloraTZP produced an average weight loss of up to 23.3% at 48 weeks in overweight or obese adults with type 2 diabetes

Zepbound adolescent trial results

  • ▪Adolescents taking Zepbound in Eli Lilly's SURMOUNT-ADOLESCENTS trial reported improvements in weight-related quality of life, including physical comfort and body esteem
  • ▪More than half of adolescent participants in Eli Lilly's SURMOUNT-ADOLESCENTS trial taking Zepbound no longer met the BMI criteria for obesity at 72 weeks
  • ▪In Eli Lilly's Phase 3 SURMOUNT-ADOLESCENTS trial, Zepbound reduced BMI by an average of 21.4% at 72 weeks in adolescents aged 12 to 18 with obesity

Foundayo trial overview and FDA plans

  • ▪Eli Lilly plans to submit its late-stage trial results for Foundayo to the U.S. FDA by the end of 2026 for U.S. approval to treat moderate-to-severe obstructive sleep apnea
  • ▪Eli Lilly announced that its daily obesity pill Foundayo reduced the severity of obstructive sleep apnea in adults with obesity or who are overweight

Foundayo sleep apnea trial results

  • ▪Eli Lilly reported that 31.5% of trial participants taking Foundayo without positive airway pressure therapy met the criteria for remission or improvement to mild obstructive sleep apnea
  • ▪In Eli Lilly's trial, Foundayo reduced the average apnea-hypopnea index at 52 weeks by 21.1 events per hour in patients not on positive airway pressure therapy compared to 4.8 for placebo and 18.3 with it compared to 5.5 for placebo
  • ▪Foundayo lowered sleep apnea-specific hypoxic burden by 55.9% in patients not using positive airway pressure therapy and by 45.8% in those using positive airway pressure therapy

Foundayo weight loss and side effects

  • ▪Eli Lilly's daily obesity pill Foundayo helped trial participants lose roughly 11% of their body weight across groups at 52 weeks and lowered a marker of inflammation
  • ▪In Eli Lilly's 52-week sleep apnea trial, 12% of participants taking Foundayo without positive airway pressure therapy discontinued due to side effects, compared to 3.8% on placebo

Obstructive sleep apnea prevalence and diagnosis

  • ▪Eli Lilly stated in a release that most people with obstructive sleep apnea have never been diagnosed
  • ▪Obstructive sleep apnea affects nearly 1 billion adults globally and 80 million people ages 20 and over in the United States, according to the National Council on Aging

2 sources

Reuters
Lilly says its obesity drugs helped patients lose weight in clinical trials | Reuters
View source article
CNBC
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
View source article

Story comments

Loading comments…

Related entities

United States

Topics

FoundaoObstructive sleep apneaEli LillyWeight loss drugsWeight managementSleep apneaObesity treatmentZepboundBlood sugar & insulinClinical trials